AxoGen

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AxoGen reports robust Q4 earnings, eyes growth through innovation

AxoGen's Q4 2022 performance showcased revenue growth, strong margins, and a focus on market expansion through core accounts.
The company's strengths lie in innovative products, high surgeon adoption rates, and a clear roadmap for future growth.
Challenges include post-COVID segment recovery, referral process acceleration, and balancing expenses with revenue.
Opportunities in rep productivity enhancement, product innovation, and regulatory milestones position AxoGen for continued success and market leadership.

AxoGen reports robust Q1 revenue growth and innovation focus

AxoGen's Q1 performance reflects strong revenue growth and market penetration strategies, supported by innovative product introductions and a clear outlook for future revenue and margin improvements.
While facing challenges in managing expenses and executing facility transitions, AxoGen's focus on niche market segments and commitment to R&D present opportunities for sustained growth and profitability.
Overall, AxoGen's strategic direction, emphasis on product innovation, and dedication to improving patient outcomes position the company well for long-term success and market expansion.

AxoGen reports revenue growth and product expansion in Q2

AxoGen's Q2 performance showed revenue growth, increased active accounts, and new product introductions.
Strengths include focus on Core Accounts, sales efforts, and no supply challenges affecting production.
Challenges include validation delay impacting gross margin and extended BLA submission timeline.
Opportunities lie in upcoming product launches, growth in scheduled procedures, and commitment to patient outcomes.

AxoGen reports robust Q3 growth driven by innovative nerve solutions

AxoGen's Q3 performance reflects strong revenue growth driven by emergent trauma and scheduled procedures, supported by a focus on core accounts and innovative products.
While challenges like a net loss persist, opportunities lie in market expansion, regulatory approvals, and maintaining revenue guidance, positioning the company for future success.
Investors should monitor AxoGen's ability to manage expenses, achieve profitability, and leverage its product innovations to drive sustainable growth and shareholder value.

AxoGen reports robust revenue growth, addresses supply chain challenges

AxoGen's strong revenue growth and product innovation demonstrate resilience and market potential.
While challenges like supply chain disruptions persist, the company's focus on cost management and customer relationships is key.
Opportunities lie in market expansion through new products and sustained revenue growth in the coming year.
Analysts are optimistic about AxoGen's performance and strategic direction, emphasizing the need for operational efficiency.

AxoGen reports revenue growth and innovation drive amidst challenges

AxoGen's Q1 2024 performance reflects revenue growth and strategic focus on core accounts and innovation. While challenges like net losses persist, opportunities lie in upcoming product approvals and enhanced transparency. The company's maintained full-year guidance indicates a positive outlook for revenue and cash flow.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evolent Health

Axogen, Evolent Health present appealing opportunities.

Analysts Recommend These 2 Falling Knives.

AxoGen's (AXGN) CEO Karen Zaderej on Q1 2019 Results - Earnings Call Transcript

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate AxoGen (AXGN) to Report a Decline in Earnings: What to Look Out for

News for AxoGen Stock (AXGN)